A detailed history of Royal Bank Of Canada transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 16,013 shares of AXSM stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,013
Previous 26,237 38.97%
Holding current value
$1.28 Million
Previous $2.09 Million 38.84%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$69.39 - $97.64 $709,443 - $998,271
-10,224 Reduced 38.97%
16,013 $1.28 Million
Q4 2023

Feb 14, 2024

BUY
$57.42 - $83.61 $366,569 - $533,766
6,384 Added 32.16%
26,237 $2.09 Million
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $867,010 - $1.03 Million
12,520 Added 170.74%
19,853 $1.39 Million
Q2 2023

Aug 14, 2023

BUY
$58.41 - $90.35 $111,504 - $172,478
1,909 Added 35.2%
7,333 $526,000
Q1 2023

May 15, 2023

SELL
$58.39 - $75.0 $172,192 - $221,175
-2,949 Reduced 35.22%
5,424 $334,000
Q4 2022

Feb 14, 2023

BUY
$39.94 - $79.72 $154,847 - $309,074
3,877 Added 86.23%
8,373 $645,000
Q3 2022

Nov 14, 2022

BUY
$36.06 - $69.85 $25,674 - $49,733
712 Added 18.82%
4,496 $201,000
Q2 2022

Aug 15, 2022

SELL
$21.74 - $46.75 $45,175 - $97,146
-2,078 Reduced 35.45%
3,784 $144,000
Q1 2022

May 16, 2022

SELL
$23.7 - $41.39 $90,154 - $157,447
-3,804 Reduced 39.35%
5,862 $242,000
Q4 2021

Feb 14, 2022

BUY
$30.7 - $43.36 $89,644 - $126,611
2,920 Added 43.28%
9,666 $365,000
Q3 2021

Nov 15, 2021

BUY
$19.91 - $68.26 $63,871 - $218,978
3,208 Added 90.67%
6,746 $223,000
Q2 2021

Aug 16, 2021

BUY
$50.63 - $73.5 $179,128 - $260,043
3,538 New
3,538 $238,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.44B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.